Last $149.80 USD
Change Today +0.75 / 0.50%
Volume 2.3M
ALXN On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $185.43
52 Week Low
06/24/13 - $87.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

1,774 Employees
Last Reported Date: 02/10/14
Founded in 1992

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Treasure...
Total Annual Compensation: $1.1M
Co-Founder, Chief Global Operations Officer a...
Total Annual Compensation: $540.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $530.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $525.0K
Compensation as of Fiscal Year 2012.

alexion pharmaceuticals inc (ALXN) Key Developments

Alexion Pharmaceuticals Inc. Announces Board Changes

Alexion Pharmaceuticals Inc. announced the appointment of John Jack T. Mollen to the Board of Directors, effective immediately. The company also announced that Joseph A. Madri, Ph.D., M.D. and Larry L. Mathis, will retire at the conclusion of the current term on May 5, 2014, after 22 years and 10 years of service to the company, respectively. Jack Mollen was most recently special advisor to the Chairman of EMC Corporation and previously served as EMC's Executive Vice President, Human Resources for 14 years. Joseph A. Madri, M.D., Ph.D., who has been a director since the company's founding in 1992, is retiring from the Board after 22 years of outstanding service to Alexion. In addition, Larry L. Mathis is also retiring from the Board after a decade of outstanding service to the company.

Alexion Pharmaceuticals, Inc. Amends and Restates By-Laws

On April 16, 2014, the Board of Directors of Alexion Pharmaceuticals, Inc. amended and restated Alexion's By-Laws to eliminate the disqualification of a proposed director nominee if the nominee is party to a compensatory arrangement with, or receives compensation or other payment from, a third party in connection with such nominee's candidacy or service. The existence of any arrangement or payment, however, must be disclosed in writing to Alexion.

Alexion Pharmaceuticals, Inc. to Present New Data on Asfotase Alfa in Infants and Juveniles with Hypophosphatasia

Alexion Pharmaceuticals, Inc. announced that researchers are scheduled to present new data from the extension phase of two clinical studies examining the long-term efficacy and safety of asfotase alfa in infants and juveniles with hypophosphatasia (HPP) at the joint meeting of the Pediatric Academic Societies (PAS) and the Asian Society for Pediatric Research, which takes place May 3-6, 2014 in Vancouver, B.C., Canada. The meeting will also feature the presentation of results from a retrospective natural history study of patients with perinatal and infantile HPP. HPP is an inherited, ultra-rare metabolic disorder that can lead to progressive damage to multiple vital organs, destruction and deformity of bones, and death. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for asfotase alfa in pediatric-onset HPP, defined as patients whose first signs or symptoms of HPP occurred prior to 18 years of age, including perinatal-, infantile-, and juvenile-onset forms of the disease. Hypophosphatasia (HPP) is a chronic, life-threatening, genetic, and ultra-rare metabolic disease characterized by defective bone mineralization that can lead to destruction and deformity of bones, profound muscle weakness, seizures, and respiratory failure. HPP is caused by a genetic deficiency of an enzyme known as tissue non-specific alkaline phosphatase (TNSALP). The genetic deficiency in HPP can affect people of all ages. HPP is traditionally classified by the age of the patient at the onset of symptoms of the disease. Patients with perinatal-onset HPP manifest their first signs of disease in utero or at birth. This form of the disease often leads to death at or soon after birth. Those patients who survive birth often have severe rickets and severely compromised respiratory function. Patients with infantile-onset HPP develop their first signs or symptoms of HPP before 6 months of age. Individuals with this form of disease develop rickets, skeletal abnormalities, fractures, failure to thrive and respiratory failure. The prognosis of these patients may be poor with mortality estimated to be as high as at 50%. Patients with juvenile-onset HPP exhibit their first signs or symptoms of HPP after 6 months of age and before 18 years of age. Individuals with this form of the disease are at risk for rickets, skeletal complications including fractures, and can have delayed acquisition of age-appropriate motor skills due to skeletal hypomineralization and muscle weakness leading to the need for walking assistance; some may never walk. Asfotase alfa is an investigational, highly innovative, first-in-class targeted enzyme replacement therapy. Asfotase alfa is designed to address the underlying cause of HPP by normalizing the genetically defective metabolic process, and preventing or reversing the severe and potentially life-threatening complications of life-long dysregulated mineral metabolism.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $149.80 USD +0.75

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Intrexon Corp $19.27 USD -0.35
MorphoSys AG €62.39 EUR 0.00
Regeneron Pharmaceuticals Inc $296.74 USD -3.40
United Therapeutics Corp $96.20 USD -2.02
Vertex Pharmaceuticals Inc $64.17 USD -0.22
View Industry Companies

Industry Analysis


Industry Average

Valuation ALXN Industry Range
Price/Earnings 100.0x
Price/Sales 19.0x
Price/Book 12.4x
Price/Cash Flow 117.0x
TEV/Sales 18.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at